Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Multiple Myeloma (US)

Analysis of: Blood-Cancer Drug Hits $1 Billion (online.wsj.com)
Despite my initial reservations Re: too frequent administrations, this is a blockbuster that is not only effective but relatively non toxic.
Analysis of: British Balance Benefit vs. Cost of Latest Drugs (www.nytimes.com)
Britain is reticent to pay for Sutent which will prolong the patients life by months.....
Analysis of: Scrutiny Grows of Drug Trials Abroad (online.wsj.com)
This article pertains to quality, accrual and safety, but in addition....
Michael Grossbard, MD, Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
Analysis of: Scientists recommend 'black box' for Avastin (www.fiercepharma.com)
In pooled data from 8000 patients across 15 studies, the risk of blood clots was increased by 12% in patients receiving Avastin.
Analysis of: Scientists recommend 'black box' for Avastin (www.fiercepharma.com)
The exact quote is " Avastin, could raise the risk of blood clots by about 12 percent."
Analysis of: PROMACTA (Brand Name Drug) FDA approval 11/20/08 (www.accessdata.fda.gov)
An oral agent that can be used in patients with ITP that have become refractory to steroids, splenectomy and various immunologic manipulations.
Analysis of: Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer (jco.ascopubs.org)
A VEGF inhibitor that appears to work well with chemo in non small cell lung carcinoma.
Analysis of: Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months (www.drugs.com)
"New data from pivotal FLEX study reveal that patients treated with Erbitux who develop early skin rash show median overall survival of 15 months (p<0.001)" This is the trial that showed Erbitux + chemo prolonged survival minimally when compared to chemo alone. Now we know the ones who develop a...
Analysis of: Roche Says Tarceva Data Promising (online.wsj.com)
Tarceva can maintain a remission in non small cell lung cancer after initial therapy with other agents. Just like Lilly's Alimta
Analysis of: Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma (jco.ascopubs.org)
Addition of Zevalin after a CR or PR in low grade, follicular lymphomas adds to CR rates and improves time to progression. The implication is that this will result in improved survivals.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 Next11 to 20 of 782

Analytics


Generated at 2009-01-07T19:00:58.307